1.60
0.03 (1.91%)
| Penutupan Terdahulu | 1.57 |
| Buka | 1.58 |
| Jumlah Dagangan | 2,387,738 |
| Purata Dagangan (3B) | 916,055 |
| Modal Pasaran | 173,036,800 |
| Harga / Jualan (P/S) | 5.53 |
| Harga / Buku (P/B) | 0.930 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Operasi (TTM) | -152.75% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -47.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.67% |
| Nisbah Semasa (MRQ) | 3.99 |
| Aliran Tunai Operasi (OCF TTM) | -20.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.12 M |
| Pulangan Atas Aset (ROA TTM) | -15.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -84.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Aclaris Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 1.25 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.66% |
| % Dimiliki oleh Institusi | 82.44% |
| Julat 52 Minggu | ||
| Median | 15.00 (837.50%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Scotiabank | 07 Mar 2025 | 15.00 (837.50%) | Beli | 1.83 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Apr 2025 | Pengumuman | Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer |
| 22 Apr 2025 | Pengumuman | Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody |
| 04 Mar 2025 | Pengumuman | Aclaris Therapeutics to Participate in Two March Healthcare Conferences |
| 27 Feb 2025 | Pengumuman | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update |
| 12 Feb 2025 | Pengumuman | New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |